CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence

Oncologist - Tập 14 Số 12 - Trang 1182-1188 - 2009
Fabrice André1,2, Weiya Xia3, Rosa Conforti1, Yongkun Wei3, Thomas Boulet4, Gorana Tomasic1, M. Spielmann1, M. Zoubir1, Narjiss Berrada1, R. Arriagada1, Gabriel N. Hortobágyi2, Mien‐Chie Hung3, Lajos Pusztai2, Suzette Delaloge1, Stefan Michiels4, Massimo Cristofanilli2
1aBreast Medical Oncology Unit, Department of Radiation Therapy, Department of Pathology and Translational Research Unit (UPRES EA03535), Institut Gustave Roussy, University of Paris XI, Villejuif, France
2bDepartment of Breast Medical Oncology
3cDepartment of Molecular and Cellular Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
4dUnit of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France

Tóm tắt

Abstract Learning Objectives After completing this course, the reader will be able to: Assess CXCR4 expression in the primary tumor for use as an indicator of a higher risk for bone metastasis in early breast cancer.Evaluate the relationship between CXCR4 expression and the occurrence of metastases in other SDF-1–producing organs, including the liver and lung.Use CXCR4 in different ways in combination with other markers to identify patients to be screened for bony metastases and/or treated preventatively for bone metastasis. This article is available for continuing medical education credit at CME.TheOncologist.com. Background. Chemokine receptor 4 (CXCR4) has been demonstrated to have a critical role in the early metastatic process. The aim of this study was to evaluate the prognostic value of CXCR4 expression in primary breast tumors and describe correlations with the occurrence of metastasis in organs expressing the CXCR4 ligand stromal cell–derived factor 1 (i.e., liver, lung, brain, and bone). Patients and Methods. CXCR4 expression in primary breast tumors was evaluated by immunohistochemistry in 823 patients included in two prospective clinical trials. CXCR4 expression was considered positive when >1% of tumor cells were stained. The prognostic value of CXCR4 expression was assessed by a Cox regression model adjusted for clinical characteristics. We assessed the association of CXCR4 expression with the rate of distant metastasis to specific organ sites. Results. CXCR4 was expressed in 92 of 794 primary tumors (12%). CXCR4 expression was not associated with clinical characteristics. CXCR4 was not prognostic for overall survival and showed a nonsignificant trend toward a higher risk for distant metastasis. CXCR4+ tumors showed a significantly higher risk for bone metastasis. The 10-year incidences of bone metastases were 23% (13.6%–32.6%) and 12% (9.7%–15%) in CXCR4+ and CXCR4− tumors, respectively. Conclusion. This study suggests that expression of CXCR4 in primary breast tumors is associated with a higher likelihood of developing bone metastases. This finding could open new avenues for the development of novel adjuvant strategies, including bone-targeting agents.

Từ khóa


Tài liệu tham khảo

Paget, 1889, The distribution of secondary growths in cancer of the breast, Lancet, 1, 99

Moser, 2001, Lymphocyte traffic control by chemokines, Nat Immunol, 2, 123, 10.1038/84219

Powles, 2006, Oral bisphosphonates as adjuvant therapy for operable breast cancer, Clin Cancer Res, 12, s6301, 10.1158/1078-0432.CCR-06-1211

Roodman, 2004, Mechanisms of bone metastasis, N Engl J Med, 350, 1655, 10.1056/NEJMra030831

Zlotnik, 2004, Chemokines in neoplastic progression, Semin Cancer Biol, 14, 181, 10.1016/j.semcancer.2003.10.004

Müller, 2001, Involvement of chemokine receptors in breast cancer metastasis, Nature, 410, 50, 10.1038/35065016

Andre, 2006, Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer, Ann Oncol, 17, 945, 10.1093/annonc/mdl053

Kang, 2003, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, 3, 537, 10.1016/S1535-6108(03)00132-6

Li, 2004, Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis, Cancer Cell, 6, 459, 10.1016/j.ccr.2004.09.027

Kaifi, 2005, Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer, J Natl Cancer Inst, 97, 1840, 10.1093/jnci/dji431

Cabioglu, 2005, Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow, Clin Exp Metastasis, 22, 39, 10.1007/s10585-005-3222-y

Orimo, 2005, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, 121, 335, 10.1016/j.cell.2005.02.034

Arriagada, 2005, Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer, Acta Oncol, 44, 458, 10.1080/02841860510029987

Contesso, 1987, The importance of histologic grade in long-term prognosis of breast cancer: A study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy, J Clin Oncol, 5, 1378, 10.1200/JCO.1987.5.9.1378

Conforti, 2007, Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: A biomarker study from two randomized trials, Ann Oncol, 18, 1477, 10.1093/annonc/mdm209

Arriagada, 1992, Competing risks determining event-free survival in early breast cancer, Br J Cancer, 66, 951, 10.1038/bjc.1992.391

Wang, 2006, The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis, Cancer Metastasis Rev, 25, 573, 10.1007/s10555-006-9019-x

Taichman, 2002, Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone, Cancer Res, 62, 1832

Geminder, 2001, A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma, J Immunol, 167, 4747, 10.4049/jimmunol.167.8.4747

Balic, 2006, Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype, Clin Cancer Res, 12, 5615, 10.1158/1078-0432.CCR-06-0169

Schabath, 2006, CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells, J Cell Sci, 119, 314, 10.1242/jcs.02741

Smid, 2006, Genes associated with breast cancer metastatic to the bone, J Clin Oncol, 24, 2261, 10.1200/JCO.2005.03.8802

Powles, 2002, Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer, J Clin Oncol, 20, 3219, 10.1200/JCO.2002.11.080

Mystakidou, 2005, Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline, Med Oncol, 22, 195, 10.1385/MO:22:2:195

Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285

Lipton, 2008, RANKL inhibition in the treatment of bone metastases, Curr Opin Support Palliat Care, 2, 197, 10.1097/SPC.0b013e32830baac2

Jones, 2006, Regulation of cancer cell migration and bone metastasis by RANKL, Nature, 440, 692, 10.1038/nature04524

Fizazi, 2009, Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 27, 1564, 10.1200/JCO.2008.19.2146

Liang, 2004, Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4, Cancer Res, 64, 4302, 10.1158/0008-5472.CAN-03-3958

Takenaga, 2004, A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma, Biochem Biophys Res Commun, 320, 226, 10.1016/j.bbrc.2004.05.155

Thông tin
Thông tin xuất bản

Oncologist

Tập 14 Số 12

1182-1188

Thông tin tác giả